Advertisement

Latest News

One COPD Exacerbation Is Too Many: Vickram Tejwani, MD

4 hours ago

For World COPD Day, Vickram Tejwani, MD, says single exacerbations warrant urgency and calls out gaps in spirometry use and initial COPD therapy.

Matching FSGS Therapy to Disease Phase, With Astrid Weins, MD, PhD

9 hours ago

Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.

Diagnosing FSGS as a Pattern of Injury, With Astrid Weins, MD, PhD

10 hours ago

A renal pathologist explains how biopsy findings, clinical context, anti-nephrin antibodies and genetics shape FSGS workup.

What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers

10 hours ago

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS

12 hours ago

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Advertisement
Advertisement